专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US08778331B2 Method of determining susceptibility of a tumor cell to a chemotherapeutic agent: novel use of herpes simplex virus 有权
标题翻译：确定肿瘤细胞对化学治疗剂敏感性的方法：单纯疱疹病毒的新用途
公开(公告)号：US08778331B2
公开(公告)日：2014-07-15
申请号：US12459332
申请日：2009-06-30
申请人： John Blaho
发明人： John Blaho
IPC分类号： A61K39/245 , C12N15/38
CPC分类号： C12Q1/6897 , C12N2710/16631 , G01N33/5011 , G01N33/5026 , G01N2333/035
摘要： The present invention provides a method of determining if a tumor cell is susceptible to killing by a chemotherapeutic agent, comprising: (a) providing a tumor cell; (b) infecting said tumor cell with a herpes simplex virus or a herpes simplex virus defective in an immediate early gene selected from the group consisting of ICP27, ICP4, and ICP22; and (c) determining the presence of apoptotic killing of said tumor cell, wherein the presence of apoptotic killing is indicative of susceptibility to said chemotherapeutic agent. Chemotherapeutic agent may include doxorubicin, etoposide, paclitaxel, cisplatin, or 5-fluorouracil. The present invention also provides a herpes simplex virus promoter construct having a lacZ gene to assess tumor resistance to chemotherapeutic agents.
摘要翻译：本发明提供了确定肿瘤细胞是否易受化学治疗剂杀伤的方法，其包括：（a）提供肿瘤细胞; （b）用选自ICP27，ICP4和ICP22的立即早期基因中的单纯疱疹病毒或单纯疱疹病毒感染所述肿瘤细胞; 和（c）确定所述肿瘤细胞的凋亡杀伤的存在，其中凋亡杀伤的存在指示对所述化学治疗剂的易感性。化疗剂可包括多柔比星，依托泊苷，紫杉醇，顺铂或5-氟尿嘧啶。本发明还提供了具有lacZ基因以评估对化学治疗剂的肿瘤抗性的单纯疱疹病毒启动子构建体。

2. 发明申请

US20160031991A1 TARGETING VACCINES FOR VETERINARY USE 审中-公开
标题翻译：用于兽医用途的疫苗
公开(公告)号：US20160031991A1
公开(公告)日：2016-02-04
申请号：US14776001
申请日：2014-03-13
申请人： VACCIBODY AS
发明人： Ole Henrik BREKKE , Mona Mari LINDEBERG , Agnete Brunsvik FREDRIKSEN
IPC分类号： C07K16/28 , C12N7/00 , A61K39/395 , C07K14/005
CPC分类号： C07K16/2833 , A61K39/3955 , C07K14/005 , C07K2317/524 , C07K2317/526 , C07K2317/53 , C07K2317/622 , C07K2317/64 , C07K2319/00 , C12N7/00 , C12N2710/16034 , C12N2710/16631
摘要： The present invention relates to therapeutic compounds, such as vaccines against avian diseases and in particular to DNA vaccines. The invention further relates to protein construct encoding homodimeric peptides, which peptides may be released from a DNA vaccine or used separately. Further described are pharmaceutical formulations, host cells and methods for producing the vaccines, as well as methods for the treatment or prevention of various diseases in animals, such as avians, such as cancers and infectious diseases.
摘要翻译：本发明涉及治疗性化合物，例如针对禽类疾病的疫苗，特别是DNA疫苗。本发明还涉及编码同二聚体肽的蛋白质构建体，该肽可以从DNA疫苗中释放或分开使用。进一步描述的是药物制剂，宿主细胞和用于生产疫苗的方法，以及用于治疗或预防动物诸如禽类如癌症和感染性疾病的各种疾病的方法。

3. 发明申请

US20140308668A1 Method of Determining Susceptibility of a Tumor Cell to a Chemotherapeutic Agent: Novel Use of Herpes SImplex Virus 审中-公开
标题翻译：确定肿瘤细胞对化疗药敏感性的方法：新型使用疱疹综合病毒
公开(公告)号：US20140308668A1
公开(公告)日：2014-10-16
申请号：US14314095
申请日：2014-06-25
申请人： Medical Diagnostic Laboratories, LLC
发明人： John Blaho
IPC分类号： C12Q1/68
CPC分类号： C12Q1/6897 , C12N2710/16631 , G01N33/5011 , G01N33/5026 , G01N2333/035
摘要： The present invention provides a method of determining if a tumor cell is susceptible to killing by a chemotherapeutic agent, comprising: (a) providing a tumor cell; (b) infecting said tumor cell with a herpes simplex virus or a herpes simplex virus defective in an immediate early gene selected from the group consisting of ICP27, ICP4, and ICP22; and (c) determining the presence of apoptotic killing of said tumor cell, wherein the presence of apoptotic killing is indicative of susceptibility to said chemotherapeutic agent. Chemotherapeutic agent may include doxorubicin, etoposide, paclitaxel, cisplatin, or 5-fluororuacil. The present invention also provides a herpes simplex virus promoter construct having a lacZ gene to assess tumor resistance to chemotherapeutic agents.
摘要翻译：本发明提供了确定肿瘤细胞是否易受化学治疗剂杀伤的方法，其包括：（a）提供肿瘤细胞; （b）用选自ICP27，ICP4和ICP22的立即早期基因中的单纯疱疹病毒或单纯疱疹病毒感染所述肿瘤细胞; 和（c）确定所述肿瘤细胞的凋亡杀伤的存在，其中凋亡杀伤的存在指示对所述化学治疗剂的易感性。化疗剂可包括多柔比星，依托泊苷，紫杉醇，顺铂或5-氟尿嘧啶。本发明还提供了具有lacZ基因以评估对化学治疗剂的肿瘤抗性的单纯疱疹病毒启动子构建体。

4. 发明申请

US20090325146A1 Method of determining susceptibility of a tumor cell to a chemotherapeutic agent: novel use of herpes 有权
标题翻译：确定肿瘤细胞对化学治疗剂的敏感性的方法：疱疹的新用途
公开(公告)号：US20090325146A1
公开(公告)日：2009-12-31
申请号：US12459332
申请日：2009-06-30
申请人： John Blaho
发明人： John Blaho
IPC分类号： C12Q1/70 , C12Q1/02 , C12Q1/68 , C12Q1/34 , C12N15/63 , C12N7/01
CPC分类号： C12Q1/6897 , C12N2710/16631 , G01N33/5011 , G01N33/5026 , G01N2333/035
摘要： The present invention provides a method of determining if a tumor cell is susceptible to killing by a chemotherapeutic agent, comprising: (a) providing a tumor cell; (b) infecting said tumor cell with a herpes simplex virus or a herpes simplex virus defective in an immediate early gene selected from the group consisting of ICP27, ICP4, and ICP22; and (c) determining the presence of apoptotic killing of said tumor cell, wherein the presence of apoptotic killing is indicative of susceptibility to said chemotherapeutic agent. Chemotherapeutic agent may include doxorubicin, etoposide, paclitaxel, cisplatin, or 5-fluorouracil. The present invention also provides a herpes simplex virus promoter construct having a lacZ gene to assess tumor resistance to chemotherapeutic agents.
摘要翻译：本发明提供了确定肿瘤细胞是否易受化学治疗剂杀伤的方法，其包括：（a）提供肿瘤细胞; （b）用选自ICP27，ICP4和ICP22的立即早期基因中的单纯疱疹病毒或单纯疱疹病毒感染所述肿瘤细胞; 和（c）确定所述肿瘤细胞的凋亡杀伤的存在，其中凋亡杀伤的存在指示对所述化学治疗剂的易感性。化疗剂可包括多柔比星，依托泊苷，紫杉醇，顺铂或5-氟尿嘧啶。本发明还提供了具有lacZ基因以评估对化学治疗剂的肿瘤抗性的单纯疱疹病毒启动子构建体。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式